FTC Praises Instacart for Ending AI Pricing Tests After $60M Settlement 
Roche CEO Warns US Drug Price Deals Could Raise Costs of New Medicines in Switzerland 
U.S. Lawmakers Urge Pentagon to Blacklist More Chinese Tech Firms Over Military Ties 
FDA Fast-Tracks Approval of Altria’s on! PLUS Nicotine Pouches Under New Pilot Program 
ByteDance Plans Massive AI Investment in 2026 to Close Gap With U.S. Tech Giants 
Saks Global Weighs Chapter 11 Bankruptcy Amid Debt Pressures and Luxury Retail Slowdown 
Uber and Baidu Partner to Test Robotaxis in the UK, Marking a New Milestone for Autonomous Ride-Hailing 
Trump Signals Push for Lower Health Insurance Prices as ACA Premium Concerns Grow 
John Carreyrou Sues Major AI Firms Over Alleged Copyrighted Book Use in AI Training 
JPMorgan’s Top Large-Cap Pharma Stocks to Watch in 2026 
Elon Musk Wins Reinstatement of Historic Tesla Pay Package After Delaware Supreme Court Ruling 
Volaris and Viva Agree to Merge, Creating Mexico’s Largest Low-Cost Airline Group 
Google and Apple Warn U.S. Visa Holders to Avoid International Travel Amid Lengthy Embassy Delays 
Bridgewater Associates Plans Major Employee Ownership Expansion in Milestone Year 
7-Eleven CEO Joe DePinto to Retire After Two Decades at the Helm 
Trump Administration Reviews Nvidia H200 Chip Sales to China, Marking Major Shift in U.S. AI Export Policy 
Italy Fines Apple €98.6 Million Over App Store Dominance 
GAITHERSBURG, Md., Dec. 06, 2016 -- Novavax, Inc., (Nasdaq:NVAX) today announced the Company will participate in the 4th Annual Guggenheim Boston Healthcare Conference.
Conference details are as follows:
Date: Tuesday, December 13, 2016
Location: Intercontinental Boston Hotel, Boston, MA
About Novavax
Novavax, Inc. (Nasdaq:NVAX) is a clinical-stage vaccine company committed to delivering novel products to prevent a broad range of infectious diseases. Our recombinant nanoparticles and Matrix-M™ adjuvant technology are the foundation for groundbreaking innovation that improves global health through safe and effective vaccines. Additional information about Novavax is available on the Company's website, novavax.com.
Contact: Novavax, Inc. Barclay A. Phillips SVP, Chief Financial Officer and Treasurer Andrea N. Flynn, Ph.D. Associate Director, Investor Relations [email protected] 240-268-2000 Russo Partners, LLC David Schull Todd Davenport, Ph.D. [email protected] [email protected] 212-845-4271
